Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: A phase 1 study Journal Article
| Authors: | Stein, E. M.; DiNardo, C. D.; Fathi, A. T.; Mims, A. S.; Pratz, K. W.; Savona, M. R.; Stein, A. S.; Stone, R. M.; Winer, E. S.; Seet, C. S.; Döhner, H.; Pollyea, D. A.; McCloskey, J. K.; Odenike, O.; Löwenberg, B.; Ossenkoppele, G. J.; Patel, P. A.; Roshal, M.; Frattini, M. G.; Lersch, F.; Franovic, A.; Nabhan, S.; Fan, B.; Choe, S.; Wang, H.; Wu, B.; Hua, L.; Almon, C.; Cooper, M.; Kantarjian, H. M.; Tallman, M. S. |
| Article Title: | Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: A phase 1 study |
| Abstract: | Ivosidenib (AG-120) and enasidenib (AG-221) are targeted oral inhibitors of the mutant isocitrate dehydrogenase (mIDH) 1 and 2 enzymes, respectively. Given their effectiveness as single agents in mIDH1/2 relapsed or refractory acute myeloid leukemia (AML), this phase 1 study evaluated the safety and efficacy of ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed mIDH1/2 AML. Ivosidenib 500 mg once daily and enasidenib 100 mg once daily were well tolerated in this setting, with safety profiles generally consistent with those of induction and consolidation chemotherapy alone. The frequency of IDH differentiation syndrome was low, as expected given the concurrent administration of cytotoxic chemotherapy. In patients receiving ivosidenib, the frequency and grades of QT interval prolongation were similar to those observed with ivosidenib monotherapy. Increases in total bilirubin were more frequently observed in patients treated with enasidenib, consistent with this inhibitor's known potential to inhibit UGT1A1, but did not appear to have significant clinical consequences. In patients receiving ivosidenib (n = 60) or enasidenib (n = 91), end-of-induction complete remission (CR) rates were 55% and 47%, respectively, and CR/CR with incomplete neutrophil or platelet recovery (CR/CRi/CRp) rates were 72% and 63%, respectively. In patients with a best overall response of CR/CRi/CRp, 16/41 (39%) receiving ivosidenib had IDH1 mutation clearance and 15/64 (23%) receiving enasidenib had IDH2 mutation clearance by digital polymerase chain reaction; furthermore, 16/20 (80%) and 10/16 (63%), respectively, became negative for measurable residual disease by multiparameter flow cytometry. |
| Keywords: | age; mutations; acute myeloid-leukemia; older |
| Journal Title: | Blood |
| Volume: | 137 |
| Issue: | 13 |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2021-04-01 |
| Start Page: | 1792 |
| End Page: | 1803 |
| Language: | English |
| ACCESSION: | WOS:000646119800013 |
| DOI: | 10.1182/blood.2020007233 |
| PROVIDER: | wos |
| PMCID: | PMC8020270 |
| PUBMED: | 33024987 |
| Notes: | Article -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work